Table 1 Patient characteristics.

From: Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer

 

Breast cancer

Breast benign disease

Healthy cohort

Total

112

19

41

Age, years

Median

51.5

46

54

Range

31–75

22–61

40–85

Mammography (BI-RADS)*

1–3

19 (20.7%)

3 (21.4%)

/

4

47 (55.2%)

11 (78.6%)

/

5

20 (24.1%)

0 (0%)

/

Ultrasound (BI-RADS)*

1–3

1 (1%)

7 (43.8%)

/

4

50 (50.5%)

9 (56.2%)

/

5

48 (49.5%)

0 (0%)

/

Serum CA15-3, U/ml*

≤25

58 (70.7%)

/

/

>25

24 (29.3%)

/

/

Serum CEA, ng/ml*

≤5.2

59 (72.0%)

/

/

>5.2

23 (28.0%)

/

/

Cancer stage

I

28 (25.0%)

/

/

II

35 (31.3%)

/

/

III

15 (13.4%)

/

/

IV

34 (30.4%)

/

/

Hormone receptor

Positive

63 (56.3%)

/

/

Negative

49 (43.8%)

/

/

HER2*

Positive

64 (57.7%)

/

/

Negative

47 (42.3%)

/

/

  1. Abbreviations: BI-RADS breast imaging reporting and data system, CA15-3 carbohydrate antigen 15-3, CEA carcino-embryonic antigen, HER2 human epidermal growth factor receptor 2.
  2. *Excluded the unknown category.
Back to article page